Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL) CEO Michael S. Anderson bought 5,000 shares of the company’s stock in a transaction on Thursday, December 7th. The shares were acquired at an average price of $8.86 per share, with a total value of $44,300.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Michael S. Anderson also recently made the following trade(s):

  • On Tuesday, September 12th, Michael S. Anderson bought 4,000 shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share stock. The shares were acquired at an average price of $9.80 per share, with a total value of $39,200.00.

Shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (AVDL) traded up $0.05 during midday trading on Monday, hitting $8.93. 456,300 shares of the stock were exchanged, compared to its average volume of 185,483. The stock has a market capitalization of $357.95, a P/E ratio of 16.54 and a beta of 1.34. Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share has a 1-year low of $7.52 and a 1-year high of $12.30. The company has a current ratio of 1.53, a quick ratio of 1.47 and a debt-to-equity ratio of 0.01.

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL) last issued its quarterly earnings results on Wednesday, November 8th. The company reported $0.09 EPS for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.13. The business had revenue of $39.68 million during the quarter, compared to the consensus estimate of $38.22 million. Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share had a net margin of 44.47% and a return on equity of 33.92%. The company’s quarterly revenue was up 23.7% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.08) earnings per share. analysts expect that Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share will post 0.28 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently modified their holdings of the company. Stifel Financial Corp grew its holdings in shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share by 4.3% during the second quarter. Stifel Financial Corp now owns 60,500 shares of the company’s stock worth $667,000 after buying an additional 2,500 shares in the last quarter. Citadel Advisors LLC purchased a new stake in shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share during the second quarter worth about $354,000. Virtu KCG Holdings LLC purchased a new stake in shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share during the second quarter worth about $259,000. JPMorgan Chase & Co. purchased a new stake in shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share during the second quarter worth about $733,000. Finally, GSA Capital Partners LLP grew its holdings in shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share by 9.9% during the second quarter. GSA Capital Partners LLP now owns 200,213 shares of the company’s stock worth $2,208,000 after buying an additional 18,056 shares in the last quarter. Institutional investors and hedge funds own 67.81% of the company’s stock.

Several research firms have weighed in on AVDL. Zacks Investment Research downgraded shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share from a “hold” rating to a “sell” rating in a report on Monday, October 16th. Langenberg & Company restated a “buy” rating and set a $30.00 target price (up from $27.00) on shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share in a report on Thursday, September 7th. Ladenburg Thalmann Financial Services raised their target price on shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share from $27.00 to $30.00 in a report on Thursday, September 7th. Finally, BidaskClub upgraded shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share from a “strong sell” rating to a “sell” rating in a report on Saturday. One research analyst has rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $21.75.

COPYRIGHT VIOLATION WARNING: “Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (AVDL) CEO Buys $44,300.00 in Stock” was first published by Watch List News and is owned by of Watch List News. If you are accessing this article on another publication, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this article can be read at https://www.watchlistnews.com/avadel-pharmaceuticals-plc-american-depositary-shares-each-representing-one-ordinary-share-avdl-ceo-buys-44300-00-in-stock/1758074.html.

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share Company Profile

Avadel Pharmaceuticals plc (NASDAQ: AVDL) is a specialty pharmaceutical company that seeks to commercialize differentiated pharmaceutical products that are safe, effective and easy to take through formulation development, by utilizing its proprietary drug delivery technology and in-licensing / acquiring new products; ultimately, helping patients adhere to their prescribed medical treatment and see better results.

Insider Buying and Selling by Quarter for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL)

Receive News & Ratings for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share and related companies with MarketBeat.com's FREE daily email newsletter.